Sinopharm offers to take China-TCM private in nearly $3 bln deal
Feb 21 (Reuters) - China National Pharmaceutical Group
has revived a take-private bid for China Traditional Chinese
Medicine Holdings 0570.HK , valuing the Hong-Kong listed
drugmaker at HK$23.16 billion ($2.96 billion).
China National Pharmaceutical, also known as Sinopharm, is
the parent of the drugmaker and had in 2021 decided against a
possible privatisation of China TCM.
($1 = 7.8215 Hong Kong dollars)
(Reporting by Rishav Chatterjee in Bengalurul; Editing by Arun
Koyyur)
((Rishav.Chatterjee@thomsonreuters.com;))
Recent news on Sinopharm
See all newsBrief: Sinopharm Group Says 9M Sinopharm Accord Net Income Attributable RMB952.5 Million (Oct 20)
Medical products distributor Sinopharm Group's prelim 9-month revenue slips
Brief: BlackRock's Long Position In H Shares Of Sinopharm Reduces To 9.23% On Oct 13, HKEX Shows
Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Brief: Sinopharm Group To Sell 30.13% Stake In China National Medicines Guorui Pharmaceutical For